CA3140170A1 - Imidazolo derivatives, compositions and methods as orexin antagonists - Google Patents
Imidazolo derivatives, compositions and methods as orexin antagonists Download PDFInfo
- Publication number
- CA3140170A1 CA3140170A1 CA3140170A CA3140170A CA3140170A1 CA 3140170 A1 CA3140170 A1 CA 3140170A1 CA 3140170 A CA3140170 A CA 3140170A CA 3140170 A CA3140170 A CA 3140170A CA 3140170 A1 CA3140170 A1 CA 3140170A1
- Authority
- CA
- Canada
- Prior art keywords
- group
- substituted
- alkyl
- halogen
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962856830P | 2019-06-04 | 2019-06-04 | |
| US62/856,830 | 2019-06-04 | ||
| PCT/US2020/035848 WO2020247445A1 (en) | 2019-06-04 | 2020-06-03 | Imidazolo derivatives, compositions and methods as orexin antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3140170A1 true CA3140170A1 (en) | 2020-12-10 |
Family
ID=73652477
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3140170A Pending CA3140170A1 (en) | 2019-06-04 | 2020-06-03 | Imidazolo derivatives, compositions and methods as orexin antagonists |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US12187737B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3972588A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2022534704A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220016918A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114286675A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020286381C1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3140170A1 (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202112827QA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020247445A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202112828SA (en) * | 2019-06-04 | 2021-12-30 | Hager Biosciences Llc | Pyrazole and imidazole derivatives, compositions and methods as orexin antagonists |
| JP2022534704A (ja) | 2019-06-04 | 2022-08-03 | ヘイガー バイオサイエンシズ,エルエルシー | オレキシンアンタゴニストとしてのイミダゾロ誘導体、組成物、及び方法 |
| KR20220119653A (ko) | 2019-12-20 | 2022-08-30 | 테나야 테라퓨틱스, 인코포레이티드 | 플루오로알킬-옥사디아졸 및 이의 용도 |
| US20240252502A1 (en) | 2021-05-04 | 2024-08-01 | Tenaya Therapeutics, Inc. | Hdac6 inhibitors for treatment of metabolic disease and hfpef |
| GB202311281D0 (en) | 2023-07-21 | 2023-09-06 | Bial Portela & Ca Sa | Orexin receptor antagonists |
| GB202311280D0 (en) | 2023-07-21 | 2023-09-06 | Bial Portela & Ca Sa | Orexin receptor antagonists |
| CN122514526A (zh) * | 2023-11-08 | 2026-08-04 | 汉阳大学校Erica产学协力团 | 一种6-芳基咪唑并[2,1-b]噻唑/噁唑-2-羧酸衍生物及含有其作为有效成分的用于治疗阿尔茨海默病的药物组合物 |
| WO2025188753A1 (en) * | 2024-03-05 | 2025-09-12 | Hager Biosciences, Llc | Pyrazole and imidazole derivatives as dual orexin and kappa-opioid receptors modulators, compositions, and methods for treating neurological and psychiatric disorders |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02237988A (ja) | 1988-11-18 | 1990-09-20 | Nissan Chem Ind Ltd | イソオキサゾロピリジン系メバロノラクトン類 |
| US5750542A (en) | 1993-09-28 | 1998-05-12 | Pfizer | Benzisoxazole and benzisothizole derivatives as cholinesterase inhibitors |
| JP3810097B2 (ja) | 1993-01-15 | 2006-08-16 | 明治製菓株式会社 | ピロリジン−2−イルカルボニル複素環式化合物誘導体 |
| CA2331735A1 (en) | 1998-05-08 | 1999-11-18 | Smithkline Beecham P.L.C. | Phenylurea and phenylthio urea derivatives |
| SK7582001A3 (en) | 1998-12-18 | 2002-03-05 | Schering Corp | Compound, method of therapy and pharmaceutical composition comprising the same, and its use for farnesyl protein transferase inhibition |
| GB0004297D0 (en) | 2000-02-23 | 2000-04-12 | Ucb Sa | 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses |
| EP1289955B1 (en) | 2000-06-16 | 2005-04-13 | Smithkline Beecham Plc | Piperidines for use as orexin receptor antagonists |
| EP1353918B1 (en) | 2000-11-28 | 2005-01-12 | Smithkline Beecham Plc | Morpholine derivatives as antagonists of orexin receptors |
| BR0209334A (pt) | 2001-05-05 | 2004-06-15 | Smithkline Beecham Plc | Aminas n-aroil cìclicas |
| GB0115862D0 (en) * | 2001-06-28 | 2001-08-22 | Smithkline Beecham Plc | Compounds |
| GB0130393D0 (en) | 2001-12-19 | 2002-02-06 | Smithkline Beecham Plc | Compounds |
| US7057042B2 (en) | 2002-05-29 | 2006-06-06 | Abbott Laboratories | Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction |
| WO2004026866A1 (en) * | 2002-09-18 | 2004-04-01 | Glaxo Group Limited | N-aroyl cyclic amines as orexin receptor antagonists |
| US20080119515A1 (en) | 2003-03-10 | 2008-05-22 | M Arshad Siddiqui | Heterocyclic Kinase Inhibitors: Methods of Use and Synthesis |
| SI1836211T1 (sl) | 2004-12-21 | 2010-04-30 | Pfizer Prod Inc | Makrolidi |
| DE102005016547A1 (de) | 2005-04-08 | 2006-10-12 | Grünenthal GmbH | Substituierte 5,6,7,8-Tetrahydro-imidazo(1,2-a)pyridin-2-ylamin-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln |
| US20090118200A1 (en) | 2005-05-23 | 2009-05-07 | Bergman Jeffrey M | Proline bis-amide orexin receptor antagonists |
| UA100974C2 (ru) * | 2006-12-01 | 2013-02-25 | Мерк Шарп Энд Доме Корп. | Соединения замещенных диазепанов как антагонисты орексиновых рецепторов |
| PE20081229A1 (es) | 2006-12-01 | 2008-08-28 | Merck & Co Inc | Antagonistas de receptor de orexina de diazepam sustituido |
| HRP20120240T1 (hr) | 2007-05-23 | 2012-04-30 | Merck Sharp & Dohme Corp. | Piridil piperidin antagonisti receptora za oreksin |
| US8106215B2 (en) | 2007-07-03 | 2012-01-31 | Actelion Pharmaceuticals Ltd. | 3-aza-bicyclo[3.3.0]octane compounds |
| ES2560095T3 (es) | 2007-08-10 | 2016-02-17 | Cortex Pharmaceuticals, Inc. | Amidas bicíclicas para mejorar las respuestas sinápticas glutamatérgicas |
| FR2925907B1 (fr) | 2008-01-02 | 2010-10-15 | Sanofi Aventis | DERIVES DE 2-HETEROAROYL-IMIDAZO°1,2-a!PYRIDINE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE |
| CN101918361B (zh) | 2008-02-12 | 2014-05-28 | 弗·哈夫曼-拉罗切有限公司 | 哌啶磺酰胺衍生物 |
| AU2009307920A1 (en) | 2008-10-21 | 2010-04-29 | Merck Sharp & Dohme Corp. | 2,3-disubstituted piperidine orexin receptor antagonists |
| AU2009307915A1 (en) | 2008-10-21 | 2010-04-29 | Merck Sharp & Dohme Corp. | 2,5-disubstituted piperidine orexin receptor antagonists |
| JP2012506374A (ja) | 2008-10-21 | 2012-03-15 | メルク・シャープ・エンド・ドーム・コーポレイション | 2,5−二置換ピペリジンオレキシン受容体アンタゴニスト |
| WO2010141275A1 (en) | 2009-06-01 | 2010-12-09 | Merck Sharp & Dohme Corp. | Pyrazine carboxamide orexin receptor antagonists |
| WO2011005636A1 (en) | 2009-07-09 | 2011-01-13 | Merck Sharp & Dohme Corp. | Tetrahydronapthyridine orexin receptor antagonists |
| MX2012009377A (es) | 2010-02-11 | 2012-09-12 | Univ Vanderbilt | Benzotiazoles y azabenzotiazoles como potenciadores alostericos mglur4, composiciones y metodos para tratar la disfuncion neurologica. |
| EP2630138B1 (en) * | 2010-10-21 | 2015-06-03 | Bayer Intellectual Property GmbH | 1-(heterocyclic carbonyl)-2-substituted pyrrolidines and their use as fungicides |
| US20120165339A1 (en) | 2010-12-22 | 2012-06-28 | Eisai R&D Management Co., Ltd. | Cyclopropane derivatives |
| ES2541531T3 (es) * | 2011-02-18 | 2015-07-21 | Actelion Pharmaceuticals Ltd. | Nuevos derivados de pirazol e imidazol útiles como antagonistas de orexina |
| EP2730573A4 (en) | 2011-07-05 | 2014-12-03 | Taisho Pharmaceutical Co Ltd | METHYLPIPERIDINDERIVAT |
| US9242995B2 (en) | 2011-10-25 | 2016-01-26 | Merck Sharp & Dohme Corp. | Isoxazolopyridine orexin receptor antagonists |
| JP6346862B2 (ja) | 2012-02-07 | 2018-06-20 | エオラス セラピューティクス, インコーポレイテッド | オレキシンレセプターアンタゴニストとしての置換プロリン/ピペリジン |
| TW201444849A (zh) | 2013-03-13 | 2014-12-01 | Janssen Pharmaceutica Nv | 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途 |
| EP4032889B1 (en) | 2013-12-20 | 2026-05-06 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| EP3187497A4 (en) | 2014-08-26 | 2018-02-07 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| JP2022534704A (ja) | 2019-06-04 | 2022-08-03 | ヘイガー バイオサイエンシズ,エルエルシー | オレキシンアンタゴニストとしてのイミダゾロ誘導体、組成物、及び方法 |
| SG11202112828SA (en) * | 2019-06-04 | 2021-12-30 | Hager Biosciences Llc | Pyrazole and imidazole derivatives, compositions and methods as orexin antagonists |
-
2020
- 2020-06-03 JP JP2021569903A patent/JP2022534704A/ja active Pending
- 2020-06-03 SG SG11202112827QA patent/SG11202112827QA/en unknown
- 2020-06-03 EP EP20818543.9A patent/EP3972588A4/en not_active Withdrawn
- 2020-06-03 US US17/616,152 patent/US12187737B2/en active Active
- 2020-06-03 WO PCT/US2020/035848 patent/WO2020247445A1/en not_active Ceased
- 2020-06-03 KR KR1020217043400A patent/KR20220016918A/ko not_active Ceased
- 2020-06-03 CN CN202080055282.9A patent/CN114286675A/zh active Pending
- 2020-06-03 CA CA3140170A patent/CA3140170A1/en active Pending
- 2020-06-03 AU AU2020286381A patent/AU2020286381C1/en not_active Expired - Fee Related
-
2024
- 2024-08-12 US US18/800,565 patent/US12187738B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US12187738B2 (en) | 2025-01-07 |
| US12187737B2 (en) | 2025-01-07 |
| CN114286675A (zh) | 2022-04-05 |
| WO2020247445A1 (en) | 2020-12-10 |
| EP3972588A4 (en) | 2023-05-31 |
| JP2022534704A (ja) | 2022-08-03 |
| EP3972588A1 (en) | 2022-03-30 |
| US20240409554A1 (en) | 2024-12-12 |
| AU2020286381B2 (en) | 2025-04-03 |
| AU2020286381A1 (en) | 2022-01-20 |
| SG11202112827QA (en) | 2021-12-30 |
| KR20220016918A (ko) | 2022-02-10 |
| AU2020286381C1 (en) | 2025-07-10 |
| US20220259224A1 (en) | 2022-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12187738B2 (en) | Imidazolo derivatives, compositions and methods as orexin antagonists | |
| US12275744B2 (en) | Pyrazole and imidazole derivatives, compositions and methods as orexin antagonists | |
| AU2013327505B2 (en) | Anti-fibrotic pyridinones | |
| CA3129067A1 (en) | Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia | |
| TW201823208A (zh) | N-醯基胺基酸化合物及其使用方法 | |
| BR112018002304B1 (pt) | Compostos de derivado de 1,3,4-oxadiazol como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos | |
| CA3018346A1 (en) | 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists | |
| EP3821947A1 (en) | Heterocyclic trpml1 agonists | |
| EP3102573A1 (en) | Substituted thiazole or oxazole p2x7 receptor antagonists | |
| WO2024044351A2 (en) | Substituted pyrazoles and imidazoles as orexin receptor antagonists composition, methods for treating neurological and psychiatric disorders | |
| WO2025188753A1 (en) | Pyrazole and imidazole derivatives as dual orexin and kappa-opioid receptors modulators, compositions, and methods for treating neurological and psychiatric disorders | |
| US20260070922A1 (en) | Pyrazole and imidazole derivatives as dual orexin and kappa-opioid receptors modulators composition, methods for treating neurological and psychiatric disorders | |
| TW202115023A (zh) | 新型細胞凋亡訊號調節激酶1抑制劑 | |
| HK40028252A (en) | Halo-allylamine ssao/vap-1 inhibitor and use thereof | |
| NZ786241A (en) | 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20240527 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250606 |
|
| B12 | Application deemed to be withdrawn, abandoned or lapsed |
Free format text: ST27 STATUS EVENT CODE: N-6-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION Effective date: 20251006 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251118 |
|
| U13 | Renewal or maintenance fee not paid |
Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE Effective date: 20260119 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260708 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260715 |